Skip to main content
. 2018 Dec 11;38(6):BSR20181693. doi: 10.1042/BSR20181693

Figure 1. The proliferation of afatinib-resistant NSCLC cell lines under afatinib treatment.

Figure 1

(A) H1650/R cells showed significant resistance to afatinib compared with H1650 cells. (B) H1975/R cells showed significant resistance to afatinib compared with H1975 cells. *Statistically significant difference (P<0.05).